Fibrate Drugs Market Size, Share, and Trends 2024 to 2033

Fibrate Drugs Market Size and Growth

The global fibrate drugs market size was USD 3.25 billion in 2023, calculated at USD 3.42 billion in 2024 and is expected to reach around USD 5.41 billion by 2033, expanding at a CAGR of 5.22% from 2024 to 2033. The global increase in the prevalence and incidence rate of cardiovascular disorders is anticipated to fuel the fibrate drugs market. The North America fibrate drugs market size reached USD 1.27 billion in 2023.

Fibrate Drugs Market Key Takeaways

• North America dominated the global fibrate drugs market with the highest revenue share of 39% in 2023.
• Europe is poised to show the fastest growth in the market during the projected period.
• By product, the branded segment has generated more than 67% of revenue share in 2023.
• By drug, the clofibrate segment dominated the market in 2023 and is anticipated to grow at the fastest rate during the forecast period.
• By distribution channel, the hospital & retail pharmacy segment led the market with a major revenue share of 40% in 2023.
• By distribution channel, the online pharmacy segment is expected to show the fastest growth in the market over the forecast period.

U.S. Fibrate Drugs Market Size and Growth 2024 to 2033

The U.S. fibrate drugs market size was exhibited at USD 890 million in 2023 and is projected to be worth around USD 1,510 million by 2033, poised to grow at a CAGR of 5.42% from 2024 to 2033.

North America dominated the global fibrate drugs market in 2023. The North American market for fibrate drugs is forecasted to grow, driven by a well-established healthcare infrastructure, a high rate of cardiovascular diseases, and extensive use of fibrate treatments for lipid disorders. The growth is further boosted by the expanding presence of major market players and a rising number of product innovations in the region.

• In July 2024, IOL Chemicals got the nod from China's drug regulator to export the cholesterol drug fenofibrate. The company's product, fenofibrate, has received approval from the National Medical Products Administration (NMPA) of China.

Europe is poised to show the fastest growth in the fibrate drugs market during the projected period. The increasing incidence of cardiovascular diseases and metabolic disorders in the region is driving the demand for effective lipid-lowering treatments. Fibrates, known for their ability to reduce triglyceride levels and boost HDL cholesterol, are becoming increasingly popular among healthcare professionals and patients alike.

Supportive regulatory policies, rising healthcare spending, and awareness campaigns are fueling the fibrate drugs market growth. As European countries emphasize preventive healthcare, the demand for fibrate medications is on the rise, which makes Europe a key player in the market's expansion.

Market Overview

Fibrate drugs are therapeutics classified as amphipathic carboxylic acids. They work by reducing triglyceride levels in the blood through the inhibition of hepatic extraction of free fatty acids, which enhances the activity of endothelial lipoprotein lipase. The growth of the fibrate drugs market is primarily driven by the rising prevalence of cardiovascular diseases globally.

The increasing number of overweight or obese individuals in developed countries, combined with sedentary lifestyles, contributes to cardiovascular disorders, further propelling the fibrate drugs market growth. Numerous clinical trials have shown that fenofibrate can elevate cholesterol and apolipoprotein levels.

Fibrate Drugs Market Growth Factors

• Increasing triglycerides among many patients are expected to drive the fibrate drugs market growth.
• Many of the population is using alcohol excessively, which increases the risk of dyslipidemia and can fuel the fibrate drugs market growth.
• Factors such as lack of exercise, high-fat diet, and smoking can lower the LDL, which can create the demand for the fibrate drugs market.
• The increasing focus of market players on the introduction of more potent drugs can propel the fibrate drugs market growth further.

Market Scope

Fibrate Drugs Market Dynamics

Driver

The increasing prevalence of diabetes worldwide

Diabetes is associated with various quantitative changes in circulating lipids, such as elevated triglycerides, increased LDL, and reduced HDL levels. Key factors contributing to diabetes include declining physical activity, urbanization, an aging population, and a rising prevalence of obesity. As diabetes becomes more widespread, the demand for fibrate drugs is anticipated to grow in the coming years. Elevated blood sugar can lead to higher triglyceride levels and lower HDL cholesterol, which subsequently raises the risk of heart disease. These long-term risks linked to diabetes are expected to drive revenue growth in the fibrate drugs market through the forecast period.

• In June 2024, Teva Pharmaceuticals launched a generic version of Novo Nordisk's (NOVOb.CO), opening a new tab Victoza to treat patients with type 2 diabetes, making it the first generic GLP-1 drug in the United States where the drug class has seen overwhelming demand.GLP-1 drugs, originally approved to treat diabetes, are also prescribed for obesity.

Restraint

Side effects of renal drugs

The adverse effects linked to renal drugs might hinder the growth of the global fibrate drugs market during the forecast period. Side effects like abdominal pain, leg cramps, headaches, and constipation can negatively impact market expansion. Additionally, the substantial costs associated with these medications pose a barrier to market growth. Expensive drugs such as Clofibrate, Gemfibrozil, and Fenofibrate can restrict market expansion due to their high prices.

Opportunity

Strategic collaborations and partnerships

Creating new fibrate formulations with improved safety and efficacy profiles aims to meet the unmatched needs of patients suffering from dyslipidemia. Expanding market presence in emerging economies with substantial patient populations and rising healthcare spending is also a key strategy. Forming strategic partnerships and collaborations for the development of combination therapies and personalized medicine approaches tailored to specific patient groups is important. Also, the integration of digital health technologies for patient monitoring and adherence to fibrate drug therapy can improve market penetration and patient outcomes.

• In December 2022, Esperion announced that the groundbreaking cholesterol lowering via fibrate medications, NEXLETOL Bempedoic acid, and an ACL-inhibiting Regimen outcomes experiment had been approved as a late-breaking clinical trial at ACC.23/WCC.

Product Type Insights

The branded segment dominated the fibrate drugs market in 2023. The increasing incidence of hyperlipidemia and associated cardiovascular diseases is driving up the demand for effective lipid-lowering drugs like fibrates. A branded medication is considered the 'innovator' or pioneer and is granted patent and exclusivity protections, which prevents immediate competition from generics. Generic drugs, however, must adhere to the same quality, strength, and purity standards as their branded counterparts. They offer the same benefits and effects.

• In January 2023, Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led, global pharmaceutical company, launched a biosimilar of the popular 10,11 anti-diabetic drug, Liraglutide, for the first time in India. The drug is being marketed under the brand name Lirafit™ following the approval from the Drug Controller General of India (DCGI).

Drug Type Insights

The clofibrate segment dominated the market in 2023 and is anticipated to grow at the fastest rate in the fibrate drugs market during the forecast period. Clofibrate has largely lost favor due to safety concerns, particularly its link to higher cancer risk. Any potential resurgence in the global market would necessitate strong scientific evidence, regulatory backing, and a significant clinical need. Regulatory approvals for generic versions have increased market competition, further driving demand.

Distribution Channel Insights

The hospital & retail pharmacy segment led the fibrate drugs market in 2023. Due to the broad availability and convenience for patients to obtain prescription medications, a greater number of individuals with cardiovascular and lipid-related conditions may result in increased hospital admissions by boosting the demand for fibrate drugs in hospital environments. Furthermore, hospitals might partner with pharmaceutical firms to ensure a continuous supply of fibrate medications and access to clinical trials or specialized formulations.

The online pharmacy segment is expected to show the fastest growth in the fibrate drugs market over the forecast period. Driven by the rising trend of digital healthcare, the ease of online prescription ordering, and the growing e-commerce sector, there is an increasing adoption of these services.

Recent Developments

• In October 2022, United Therapeutics Corporation announced the EXPEDITE study of Remodulin induction prior to Orenitram therapy's top line. Teprostinil exposure is increased when organigram and the CYP2C8 enzyme inhibitor gemfibrozil are taken together.
• In February 2022, the Food and Drug Administration (FDA) expanded approval of empagliflozin (Jardiance) for use in adults with heart failure (HF), regardless of ejection fraction, to reduce the risk of cardiovascular death and HF hospitalization.
• In May 2022, Amgen reported positive data from the Phase 2 OCEAN(a)-DOSE clinical study evaluating olpasiran (formerly AMG 890) in 281 adult patients with lipoprotein(a), or Lp(a), levels greater than 150 nmol/L. disclosed evidence of atherosclerotic cardiovascular disease (ASCVD).

Fibrate Drugs Market Companies

• Teva Pharmaceutical Industries
• Pfizer Inc.
• Mylan N.V.
• Sanofi SA
• Novartis AG
• GlaxoSmithKline plc
• Sun Pharmaceutical Industries Inc.
• Macleods Pharmaceuticals Limited
• Aurobindo Pharma
• Abbott

Segments Covered in the Report

By Drug Type

• Clofibrate
• Gemfibrozil
• Fenofibrate
• Others

By Product Type

• Branded
• Generics

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa